Cabaletta Bio Inc (CABA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cabaletta Bio Inc (CABA) has a cash flow conversion efficiency ratio of -0.197x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.51 Million) by net assets ($210.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cabaletta Bio Inc (CABA) market capitalisation for the company's overall valuation and market capitalisation.
Cabaletta Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Cabaletta Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cabaletta Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cabaletta Bio Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Cabaletta Bio Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Powerlaw Corp. Common Stock
NASDAQ:PWRL
|
N/A |
|
Nam Long Investment Corp
VN:NLG
|
0.009x |
|
Regulus Resources Inc
V:REG
|
-0.007x |
|
Weltrend Semiconductor Inc
TW:2436
|
0.019x |
|
Mekonomen AB
ST:MEKO
|
0.035x |
|
Shanghai Tianchen Co Ltd
SHG:600620
|
-0.040x |
|
Aerostar Bacau
RO:ARS
|
N/A |
|
Levinstein Eng
TA:LEVI
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Cabaletta Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cabaletta Bio Inc from 2017 to 2025. View Cabaletta Bio Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.05 Million | $-131.08 Million | -1.170x | -102.00% |
| 2024-12-31 | $152.34 Million | $-88.22 Million | -0.579x | -155.45% |
| 2023-12-31 | $236.20 Million | $-53.55 Million | -0.227x | +48.91% |
| 2022-12-31 | $104.52 Million | $-46.38 Million | -0.444x | -53.46% |
| 2021-12-31 | $117.96 Million | $-34.11 Million | -0.289x | -18.33% |
| 2020-12-31 | $109.54 Million | $-26.77 Million | -0.244x | -110.67% |
| 2019-12-31 | $138.32 Million | $-16.05 Million | -0.116x | -126.60% |
| 2018-12-31 | $-10.69 Million | $-4.66 Million | 0.436x | -97.67% |
| 2017-12-31 | $-249.00K | $-4.66 Million | 18.719x | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more